Evidence map›Paper›PMID 30584466›Full record

ArticleOxidative medicine and cellular longevity2018

Low Serum Tryptophan Levels as an Indicator of Global Cognitive Performance in Nondemented Women over 50 Years of Age.

L A Ramos-Chávez, G Roldán-Roldán, B García-Juárez, D González-Esquivel, G Pérez de la Cruz, B Pineda, D Ramírez-Ortega, I García Muñoz, B Jiménez Herrera, C Ríos and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Phenotypic and metabonomics studies of FMOs in C. elegans and their roles in lifespan extension.Metabolomics : Official journal of the Metabolomic Society · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Metabolomic heterogeneity of ageing with ethnic diversity: a step closer to healthy ageing.Metabolomics : Official journal of the Metabolomic Society · 2024
    Article
  10. Article
  11. The Aging Process: A Metabolomics Perspective.Molecules (Basel, Switzerland) · 2022
    Article
  12. Review
  13. Article
  14. Article
  15. The Role of Tryptophan Metabolites in Neuropsychiatric Disorders.International journal of molecular sciences · 2022
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

L A Ramos-ChávezLaboratorio de Neurobiología de la Conducta, Departamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico.
G Roldán-RoldánLaboratorio de Neurobiología de la Conducta, Departamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico.ORCID 0000-0003-1356-6428
B García-JuárezDivisión de Neurociencias/Subdivisión de Neurobiología, Instituto Nacional de Rehabilitación S.S.A., México, DF 14389, Mexico.
D González-EsquivelDepartamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, S.S.A., México, DF 14269, Mexico.ORCID 0000-0001-8262-3399
G Pérez de la CruzInstituto Nacional de Estadística y Geografía (INEGI), México, DF 03730, Mexico.ORCID 0000-0002-4268-0142
B PinedaLaboratorio de Neuroinmunología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, S.S.A., México, DF 14269, Mexico.ORCID 0000-0002-1455-312X
D Ramírez-OrtegaDepartamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, S.S.A., México, DF 14269, Mexico.ORCID 0000-0001-8610-7404
I García MuñozDivisión de Rehabilitación Geriátrica, Instituto Nacional de Rehabilitación, Ciudad de México, S.S.A. 14389, Mexico.
B Jiménez HerreraDivisión de Rehabilitación Geriátrica, Instituto Nacional de Rehabilitación, Ciudad de México, S.S.A. 14389, Mexico.
C RíosDepartamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, S.S.A., México, DF 14269, Mexico.
S Gómez-ManzoLaboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, México City 04530, Mexico.
J Marcial-QuinoCONACYT-Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México 04530, Mexico.
L Sánchez ChapulLaboratorio de Enfermedades Neuromusculares, Instituto Nacional de Rehabilitación, Ciudad de Mexico, S.S.A. 14389, Mexico.
P Carrillo MoraDivisión de Neurociencias/Subdivisión de Neurobiología, Instituto Nacional de Rehabilitación S.S.A., México, DF 14389, Mexico.ORCID 0000-0002-3178-7016
V Pérez de la CruzDepartamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, S.S.A., México, DF 14269, Mexico.ORCID 0000-0002-1451-8754
Instituto Nacional de Neurología y Neurocirugía · MXInstituto Nacional de Rehabilitación · MXSecretaria de Salud · MXNational Institute of Statistics and Geography · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aging is a physiological decline process. The number of older adults is growing around the world; therefore, the incidence of cognitive impairment, dementia, and other diseases related to aging increases. The main cellular factors that converge in the aging process are mitochondrial dysfunction, antioxidant impairment, inflammation, and immune response decline, among others. In this context, these cellular changes have an influence on the kynurenine pathway (KP), the main route of tryptophan (Trp) catabolism. KP metabolites have been involved in the aging process and neurodegenerative diseases. Although there are changes in the metabolite levels with age, at this time, there is no study that has evaluated cognitive decline as a consequence of Trp catabolism fluctuation in aging. The aim of this study was to evaluate the relation between the changes in Trp catabolism and cognitive impairment associated with age through KP metabolites level alterations in women over 50 years of age. Seventy-seven nondemented women over 50 years old were examined with a standardized cognitive screening evaluation in Spanish language (Neuropsi), Beck anxiety inventory (BAI), and the geriatric depression scale (GDS). Also, serum levels of Trp, kynurenine (Kyn), kynurenic acid (KYNA), and 3-hydroykynurenine (3-HK) and the glutathione ratio (GSH/GSSG) were measured. Results showed a negative correlation between age and Trp levels and a positive correlation between age and KYNA/Trp and 3-HK/Trp ratios. The level of cognitive impairment showed a significant positive association with age and with kynurenine pathway activation and a significant negative correlation with Trp levels. The GSH/GSSG ratio correlated positively with Trp levels and negatively with Kyn/Trp and 3-HK/Trp ratios. The depression score correlated negatively with Trp and positively with the 3-HK/Trp ratio. We concluded that KP activation increases with age and it is strongly associated with the level of cognition performance in nondemented women over 50 years of age.

Indexed as

AgedAged, 80 and overCognitionFemaleHumansKynurenic AcidKynurenineMiddle AgedQuinolinic AcidTryptophanKynurenic AcidKynurenineQuinolinic AcidTryptophan

Identifiers

PMID30584466
PMCPMC6280300
OpenAlexW2900634238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.